The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl

Derington, Catherine G.; Bress, Adam P.; Herrick, Jennifer S.; Fan, Wenjun; Wong, Nathan D.; Andrade, Katherine E; Johnson, Jonathan; Philip, Sephy; Abrahamson, David; Jiao, Lixia; Bhatt, Deepak L.; Weintraub, William S.

doi:10.1016/j.ajpc.2022.100345

Cited by 4 publications

(1 citation statement)

References 29 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This low use is consistent with other recent real-world data. A recent study by Derington et al created cohorts using the National Health and Nutrition Examination Surveys (NHANES) 2009–2014 and the Optum Research Database (ORD) to see how many participants were eligible to receive icosapent ethyl [ 22 ]. They estimated 3.6 million US adults to be eligible and observed that the 5-year first event (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization, or coronary revascularization) rate without IPE was 19.0% compared to 13.1% with 5 years of IPE treatment, preventing 212,000 events.…”

Section: Discussionmentioning

confidence: 99%

Dyslipidemia Treatment and Lipid Control in US Adults with Diabetes by Sociodemographic and Cardiovascular Risk Groups in the NIH Precision Medicine Initiative All of Us Research Program

Akbarpour

Devineni

Gong

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Real-world data on lipid levels and treatment among adults with diabetes mellitus (DM) are relatively limited. We studied lipid levels and treatment status in patients with DM across cardiovascular disease (CVD) risk groups and sociodemographic factors. In the All of Us Research Program, we categorized DM as (1) moderate risk (≤1 CVD risk factor), (2) high risk (≥2 CVD risk factors), and (3) DM with atherosclerotic CVD (ASCVD). We examined the use of statin and non-statin therapy as well as LDL-C and triglyceride levels. We studied 81,332 participants with DM, which included 22.3% non-Hispanic Black and 17.2% Hispanic. A total of 31.1% had ≤1 DM risk factor, 30.3% had ≥2 DM risk factors, and 38.6% of participants had DM with ASCVD. Only 18.2% of those with DM and ASCVD were on high-intensity statins. Overall, 5.1% were using ezetimibe and 0.6% PCSK9 inhibitors. Among those with DM and ASCVD, only 21.1% had LDL-C < 70 mg/dL. Overall, 1.9% of participants with triglycerides ≥ 150 mg/dL were on icosapent ethyl. Those with DM and ASCVD were more likely to be on high-intensity statins, ezetimibe, and icosapent ethyl. Guideline-recommended use of high-intensity statins and non-statin therapy among our higher risk DM patients is lacking, with LDL-C inadequately controlled.

show abstract

Section: Discussionmentioning

confidence: 99%